CC及CXC趋化因子在肿瘤微环境中的作用及治疗潜力

doi:10.3760/cma.j.cn371439-20250528-00037

摘要/Abstract

摘要：

趋化因子是一类具有趋化功能的细胞因子，通过与受体结合在肿瘤微环境中发挥重要作用。其在肿瘤进展中的功能机制主要包括促进肿瘤细胞增殖和转移的信号通路激活，调控肿瘤血管生成以改变血液供应和营养状态，介导免疫逃逸以规避宿主防御系统。研究证实，靶向特定趋化因子-受体轴可有效抑制肿瘤细胞恶性行为，并调控免疫细胞浸润，展现出显著的抗肿瘤效应。CC和CXC类趋化因子调控网络在肿瘤微环境中的关键作用及其靶向治疗策略研究，为恶性肿瘤的临床治疗提供了重要的理论基础和应用前景。

关键词: 趋化因子，CC, 趋化因子，CXC, 肿瘤微环境, 肿瘤逃逸, 免疫疗法

Abstract:

Chemokines are a class of cytokines with chemotactic functions that play important roles in the tumor microenvironment through receptor binding. Their functional mechanisms in tumor progression mainly include activating signaling pathways to promote tumor cell proliferation and metastasis， regulating tumor angiogenesis to alter blood supply and nutritional status， and mediating immune escape to evade host defense systems. Studies have demonstrated that targeting specific chemokine-receptor axes can effectively inhibit malignant behaviors of tumor cells and regulate immune cell infiltration， showing significant anti-tumor effects. Research on the critical roles of CC and CXC chemokines regulatory networks in the tumor microenvironment and their targeted therapeutic strategies provides an important theoretical basis and clinical application prospects for the treatment of malignant tumors.

Key words: Chemokines， CC, Chemokines， CXC, Tumor microenvironment, Tumor escape, Immunotherapy

杨心茹, 曹莉莉. CC及CXC趋化因子在肿瘤微环境中的作用及治疗潜力[J]. 国际肿瘤学杂志, 2026, 53(4): 224-228.

Yang Xinru, Cao Lili. Role and therapeutic potential of CC and CXC chemokines in the tumor microenvironment[J]. Journal of International Oncology, 2026, 53(4): 224-228.

图/表 1

表1

参考文献 55

[1]	Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263. DOI: 10.3322/caac.21834.
[2]	Wu H, Zhang XX, Han DL, et al. Tumour-associated macrophages mediate the invasion and metastasis of bladder cancer cells through CXCL8[J]. PeerJ, 2020, 8: e8721. DOI: 10.7717/peerj.8721.
[3]	Wang Z, Yang Y, Cui YC, et al. Tumor-associated macrophages regulate gastric cancer cell invasion and metastasis through TGFβ2/NF-κB/Kindlin-2 axis[J]. Chin J Cancer Res, 2020, 32(1): 72-88. DOI: 10.21147/j.issn.1000-9604.2020.01.09.
[4]	Bule P, Aguiar SI, Aires-Da-Silva F, et al. Chemokine-directed tumor microenvironment modulation in cancer immunotherapy[J]. Int J Mol Sci, 2021, 22(18): 9804. DOI: 10.3390/ijms22189804.
[5]	Li H. Update on the role of chemokines and chemokine receptors in liver fibrosis[J]. J Gastrointestin Liver Dis, 2023, 32(2): 241-256. DOI: 10.15403/jgld-4660. pmid: 37345599
[6]	Wang JX, Saung MT, Li K, et al. CCR2/CCR5 inhibitor permits the radiation-induced effector T cell infiltration in pancreatic adenocarcinoma[J]. J Exp Med, 2022, 219(5): e20211631. DOI: 10.1084/jem.20211631.
[7]	Yoshimura T, Li C, Wang Y, et al. The chemokine monocyte chemoattractant protein-1/CCL2 is a promoter of breast cancer metastasis[J]. Cell Mol Immunol, 2023, 20(7): 714-738. DOI: 10.1038/s41423-023-01013-0. pmid: 37208442
[8]	Kodama T, Koma YI, Arai N, et al. CCL3-CCR5 axis contributes to progression of esophageal squamous cell carcinoma by promoting cell migration and invasion via Akt and ERK pathways[J]. Lab Invest, 2020, 100(9): 1140-1157. DOI: 10.1038/s41374-020-0441-4. pmid: 32457351
[9]	Ma X, Su J, Zhao S, et al. CCL3 Promotes proliferation of colorectal cancer related with TRAF6/NF-κB molecular pathway[J]. Contrast Media Mol Imaging, 2022, 2022: 2387192. DOI: 10.1155/2022/2387192.
[10]	Gilchrist A, Echeverria SL. Targeting chemokine receptor CCR1 as a potential therapeutic approach for multiple myeloma[J]. Front Endocrinol (Lausanne), 2022, 13: 846310. DOI: 10.3389/fendo.2022.846310.
[11]	Brett E, Duscher D, Pagani A, et al. Naming the barriers between anti-CCR5 therapy, breast cancer and its microenvironment[J]. Int J Mol Sci, 2022, 23(22): 14159. DOI: 10.3390/ijms232214159.
[12]	Bademler S, Kılıç B, Üçüncü M, et al. The role of biomarkers in the early diagnosis of gastric cancer: a study on CCR5, CCL5, PDGF, and ephA7[J]. Curr Issues Mol Biol, 2024, 46(9): 10651-10661. DOI: 10.3390/cimb46090632. pmid: 39329983
[13]	Huang R, Guo L, Gao MH, et al. Research trends and regulation of CCL5 in prostate cancer[J]. Onco Targets Ther, 2021, 14: 1417-1427. DOI: 10.2147/OTT.S279189.
[14]	Pervaiz A, Zepp M, Georges R, et al. Antineoplastic effects of targeting CCR5 and its therapeutic potential for colorectal cancer liver metastasis[J]. J Cancer Res Clin Oncol, 2021, 147(1): 73-91. DOI: 10.1007/s00432-020-03382-9.
[15]	Sun JR, Feng QM, He Y, et al. Lactate activates CCL18 expression via H3K18 lactylation in macrophages to promote tumorigenesis of ovarian cancer[J]. Acta Biochim Biophys Sin (Shanghai), 2024, 56(9): 1373-1386. DOI: 10.3724/abbs.2024111.
[16]	Chen PX, Wang HW, Tang ZR, et al. Selective depletion of CCR8⁺ Treg cells enhances the antitumor immunity of cytotoxic T cells in lung cancer by dendritic cells[J]. J Thorac Oncol, 2025, 20(8): 1050-1074. DOI: 10.1016/j.jtho.2025.02.029.
[17]	Chen YH, Chu CC, Liu JF, et al. C-X-C motif ligand 1 induces cell migration by upregulating ICAM-1 expression by activating PI3K/Akt and NF-κB signaling pathway in liver cancer[J]. Adv Biol (Weinh), 2025, 9(3): e2400295. DOI: 10.1002/adbi.202400295.
[18]	Huang C, Chen B, Wang X, et al. Gastric cancer mesenchymal stem cells via the CXCR2/HK2/PD-L1 pathway mediate immunosuppression[J]. Gastric Cancer, 2023, 26(5): 691-707. DOI: 10.1007/s10120-023-01405-1. pmid: 37300724
[19]	Fu XR, Wang QM, Du H, et al. CXCL8 and the peritoneal metastasis of ovarian and gastric cancer[J]. Front Immunol, 2023, 14: 1159061. DOI: 10.3389/fimmu.2023.1159061.
[20]	Nie G, Cao XB, Mao Y, et al. Tumor-associated macrophages-mediated CXCL8 infiltration enhances breast cancer metastasis: suppression by Danirixin[J]. Int Immunopharmacol, 2021, 95: 107153. DOI: 10.1016/j.intimp.2020.107153.
[21]	Zhao HP, Yao T, Wei MZ, et al. CXCL12 deficiency promotes colorectal cancer progression and reduces anti-PD-L1 immunotherapy efficacy through MDSC regulation[J]. J Transl Med, 2025, 23(1): 1378. DOI: 10.1186/s12967-025-07309-1.
[22]	Heidegger I, Fotakis G, Offermann A, et al. Comprehensive characterization of the prostate tumor microenvironment identifies CXCR4/CXCL12 crosstalk as a novel antiangiogenic therapeutic target in prostate cancer[J]. Mol Cancer, 2022, 21(1): 132. DOI: 10.1186/s12943-022-01597-7. pmid: 35717322
[23]	Suarez-Carmona M, Williams A, Schreiber J, et al. Combined inhibition of CXCL12 and PD-1 in MSS colorectal and pancreatic cancer: modulation of the microenvironment and clinical effects[J]. J Immunother Cancer, 2021, 9(10): e002505. DOI: 10.1136/jitc-2021-002505.
[24]	Yang JZ, Lu HF, Li LJ. Chemokines: orchestration of the tumor microenvironment and control of hepatocellular carcinoma progression[J]. Cancer Med, 2025, 14(7): e70789. DOI: 10.1002/cam4.70789.
[25]	Fang WB, Sofia AD, Smart C, et al. Expression of CCL2/CCR2 signaling proteins in breast carcinoma cells is associated with invasive progression[J]. Sci Rep, 2021, 11(1): 8708. DOI: 10.1038/s41598-021-88229-0. pmid: 33888841
[26]	Zeng Z, Lan TX, Wei YQ, et al. CCL5/CCR5 axis in human diseases and related treatments[J]. Genes Dis, 2022, 9(1): 12-27. DOI: 10.1016/j.gendis.2021.08.004.
[27]	Huang R, Wang S, Wang N, et al. CCL5 derived from tumor-associated macrophages promotes prostate cancer stem cells and metastasis via activating β-catenin/STAT3 signaling[J]. Cell Death Dis, 2020, 11(4): 234. DOI: 10.1038/s41419-020-2435-y. pmid: 32300100
[28]	Li F, Du XF, Lan F, et al. Eosinophilic inflammation promotes CCL6-dependent metastatic tumor growth[J]. Sci Adv, 2021, 7(22): eabb5943. DOI: 10.1126/sciadv.abb5943.
[29]	Chen XM, An Y, Zhang Y, et al. CCL26 is upregulated by nab-paclitaxel in pancreatic cancer-associated fibroblasts and promotes PDAC invasiveness through activation of the PI3K/AKT/mTOR pathway[J]. Acta Biochim Biophys Sin (Shanghai), 2021, 53(5): 612-619. DOI: 10.1093/abbs/gmab032.
[30]	Qu R, Zhao YH, Zhang YZ. The mechanism of cytokine regulation of cancer occurrence and development in the tumor microenvironment and its application in cancer treatment: a narrative review[J]. Transl Cancer Res, 2024, 13(10): 5649-5663. DOI: 10.21037/tcr-24-679. pmid: 39525000
[31]	O'Connor T, Heikenwalder M. CCL2 in the tumor microenvironment[J]. Adv Exp Med Biol, 2021, 1302: 1-14. DOI: 10.1007/978-3-030-62658-7_1. pmid: 34286437
[32]	Yu D, Xu HZ, Zhou JZ, et al. PDPN/CCL2/STAT3 feedback loop alter CAF heterogeneity to promote angiogenesis in colorectal cancer[J]. Angiogenesis, 2024, 27(4): 809-825. DOI: 10.1007/s10456-024-09941-9. pmid: 39115624
[33]	Zhang XF, Zhang XL, Wang YJ, et al. The regulatory network of the chemokine CCL5 in colorectal cancer[J]. Ann Med, 2023, 55(1): 2205168. DOI: 10.1080/07853890.2023.2205168.
[34]	Korbecki J, Kojder K, Siminska D, et al. CC Chemokines in a tumor: a review of pro-cancer and anti-cancer properties of the ligands of receptors CCR1, CCR2, CCR3, and CCR4[J]. Int J Mol Sci, 2020, 21(21): 8412. DOI: 10.3390/ijms21218412.
[35]	Yang H, Zhang QN, Xu M, et al. CCL2-CCR2 axis recruits tumor associated macrophages to induce immune evasion through PD-1 signaling in esophageal carcinogenesis[J]. Mol Cancer, 2020, 19(1): 41. DOI: 10.1186/s12943-020-01165-x. pmid: 32103760
[36]	Chen S, Huang CS, Li K, et al. Tumor-initiating cells escape tumor immunity via CCL8 from tumor-associated macrophages in mice[J]. J Clin Invest, 2025, 135(5): e180893. DOI: 10.1172/JCI180893.
[37]	Chen BY, Song L, Nie XZ, et al. CXCL1 Regulated by miR-302e is involved in cell viability and motility of colorectal cancer via inhibiting JAK-STAT signaling pathway[J]. Front Oncol, 2021, 10: 577229. DOI: 10.3389/fonc.2020.577229.
[38]	Deng J, Jiang RQ, Meng EQ, et al. CXCL5: a coachman to drive cancer progression[J]. Front Oncol, 2022, 12: 944494. DOI: 10.3389/fonc.2022.944494.
[39]	Yang LY, Liu L, Zhang R, et al. IL-8 mediates a positive loop connecting increased neutrophil extracellular traps (NETs) and colorectal cancer liver metastasis[J]. J Cancer, 2020, 11(15): 4384-4396. DOI: 10.7150/jca.44215. pmid: 32489457
[40]	Yang YR, Li JY, Lei WR, et al. CXCL12-CXCR4/CXCR7 axis in cancer: from mechanisms to clinical applications[J]. Int J Biol Sci, 2023, 19(11): 3341-3359. DOI: 10.7150/ijbs.82317. pmid: 37497001
[41]	Han J, Fu RJ, Chen C, et al. CXCL16 promotes gastric cancer tumorigenesis via ADAM10-dependent CXCL16/CXCR6 axis and activates Akt and MAPK signaling pathways[J]. Int J Biol Sci, 2021, 17(11): 2841-2852. DOI: 10.7150/ijbs.57826. pmid: 34345211
[42]	Grytsai O, Dufies M, Le Du J, et al. A potent solution for tumor growth and angiogenesis suppression via an ELR⁺CXCL-CXCR1/2 pathway inhibitor[J]. ACS Med Chem Lett, 2024, 15(6): 845-856. DOI: 10.1021/acsmedchemlett.4c00053.
[43]	Masrour M, Moeinafshar A, Poopak A, et al. The role of CXC chemokines and receptors in breast cancer[J]. Clin Exp Med, 2025, 25(1): 128. DOI: 10.1007/s10238-025-01662-7. pmid: 40278951
[44]	Korbecki J, Bosiacki M, Barczak K, et al. Involvement in tumorigenesis and clinical significance of CXCL1 in reproductive cancers: breast cancer, cervical cancer, endometrial cancer, ovarian cancer and prostate cancer[J]. Int J Mol Sci, 2023, 24(8): 7262. DOI: 10.3390/ijms24087262.
[45]	Mao P, Wang T, Du CW, et al. CXCL5 promotes tumorigenesis and angiogenesis of glioblastoma via JAK-STAT/NF-κB signaling pathways[J]. Mol Biol Rep, 2023, 50(10): 8015-8023. DOI: 10.1007/s11033-023-08671-3. pmid: 37541997
[46]	Korbecki J, Bajdak-Rusinek K, Kupnicka P, et al. The role of CXCL16 in the pathogenesis of cancer and other diseases[J]. Int J Mol Sci, 2021, 22(7): 3490. DOI: 10.3390/ijms22073490.
[47]	Wang XM, Zhang YY, Wang S, et al. The role of CXCR3 and its ligands in cancer[J]. Front Oncol, 2022, 12: 1022688. DOI: 10.3389/fonc.2022.1022688.
[48]	Ciummo SL, D'Antonio L, Sorrentino C, et al. The C-X-C motif chemokine ligand 1 sustains breast cancer stem cell self-renewal and promotes tumor progression and immune escape programs[J]. Front Cell Dev Biol, 2021, 9: 689286. DOI: 10.3389/fcell.2021.689286.
[49]	Wan YF, Ge K, Zhou WJ, et al. C-X-C chemokine receptor 2 (CXCR2) promotes hepatocellular carcinoma immune evasion via regulating programmed death-ligand 1 (PD-L1)[J]. Biol Chem, 2021, 402(6): 729-737. DOI: 10.1515/hsz-2020-0328. pmid: 33583159
[50]	Xiong G, Chen Z, Liu QW, et al. CD276 regulates the immune escape of esophageal squamous cell carcinoma through CXCL1-CXCR2 induced NETs[J]. J Immunother Cancer, 2024, 12(5): e008662. DOI: 10.1136/jitc-2023-008662.
[51]	Sarkar T, Dhar S, Sa G. Tumor-infiltrating T-regulatory cells adapt to altered metabolism to promote tumor-immune escape[J]. Curr Res Immunol, 2021, 2: 132-141. DOI: 10.1016/j.crimmu.2021.08.002.
[52]	Sun DT, Tan LP, Chen YB, et al. CXCL5 impedes CD8⁺ T cell immunity by upregulating PD-L1 expression in lung cancer via PXN/AKT signaling phosphorylation and neutrophil chemotaxis[J]. J Exp Clin Cancer Res, 2024, 43(1): 202. DOI: 10.1186/s13046-024-03122-8.
[53]	Chen QD, Yin HL, Pu N, et al. Chemokine C-C motif ligand 21 synergized with programmed death-ligand 1 blockade restrains tumor growth[J]. Cancer Sci, 2021, 112(11): 4457-4469. DOI: 10.1111/cas.15110.
[54]	Yang SN, Yu JX, Dong X, et al. CCR2 signaling regulates anti-chlamydia T cell immune responses in the airway[J]. PLoS Pathog, 2025, 21(2): e1012912. DOI: 10.1371/journal.ppat.1012912.
[55]	Wang S, Wang XJ, Liu S, et al. The CXCR4 antagonist, AMD3100, reverses mesenchymal stem cell-mediated drug resistance in relapsed/refractory acute lymphoblastic leukemia[J]. Onco Targets Ther, 2020, 13: 6583-6591. DOI: 10.2147/OTT.S249425.

典型成员	主要受体	高表达肿瘤类型	TME中的核心功能	临床关联性与治疗策略
CC亚家族
CCL2	CCR2	胰腺癌^[6]、乳腺癌、胶质瘤^[7]	招募肿瘤相关巨噬细胞（M2型）、促进血管生成、免疫抑制	放疗+抗PD-1抗体+CCR2/5抑制剂联合疗法可显著提高胰腺癌的抗肿瘤疗效^[6]
CCL3	CCR1/CCR5	食管鳞状细胞癌^[8]、结直肠癌^[9]	促进肿瘤相关巨噬细胞浸润、增强肿瘤侵袭性	CCR1拮抗剂（CCX721）可抑制骨髓瘤转移^[10]
CCL5	CCR5	乳腺癌^[11]、胃癌^[12]、前列腺癌^[13]	诱导调节性T细胞/髓源性抑制细胞募集、促进远处转移	CCR5抑制剂（马拉维罗）可显著改善结直肠癌肝转移模型的治疗效果^[14]
CCL18	CCR8	卵巢癌^[15]	驱动上皮间质转化、增强肿瘤相关巨噬细胞介导的免疫逃逸	抗CCR8单克隆抗体与PD-1抑制剂联合使用可显著抑制非小细胞肺癌肿瘤的生长^[16]
CXC亚家族
CXCL1	CXCR2	黑色素瘤、乳腺癌、肺癌、胰腺癌、结直肠癌、肝癌^[17]	招募中性粒细胞、促进血管生成	CXCR2抑制剂（AZD5069）可提升抗PD-1免疫疗法对胃癌的抗肿瘤疗效^[18]
CXCL8	CXCR1/2	胃癌、卵巢癌、结直肠癌、乳腺癌、前列腺癌^[19]	上调PD-L1、抑制CD8⁺ T细胞功能	CXCR2抑制剂通过抑制CXCL8/CXCR2信号通路可有效减缓乳腺癌的生长^[20]
CXCL12	CXCR4/7	结直肠癌^[21]、前列腺癌^[22]	介导肿瘤干细胞休眠、保护化疗抵抗	CXCL12抑制剂（NOX-A12）与帕博利珠单抗联合对微卫星稳定转移性结直肠癌和胰腺癌有显著的疗效^[23]